Movement Alert｜Innovent Biologics Rises 3.01% in Regular Trading, IBI3003 Phase III First Patient Dosing Continues to Drive Sentiment

Market Focus06-24

On June 24, Innovent Biologics rose 3.01% in regular trading, trading at HKD 78.3/share, with turnover of HKD 64.46 million. The stock extended gains following the company's announcement that IBI3003, a GPRC5D/BCMA/CD3 trispecific antibody for the treatment of multiple myeloma, completed first patient dosing in its pivotal Phase III clinical trial.

This milestone marks a critical step toward clinical application for the innovative therapy. The catalyst has sustained market enthusiasm over consecutive sessions. Meanwhile, the broader biotechnology sector rallied in tandem, with BeiGene up 2.86% and Akeso up 1.4%, providing additional sector-level support. Separately, JPMorgan recently increased its position in the company by approximately 1.07 million shares at HKD 75.40 per share, while Xingye Securities maintained a Buy rating, citing strong pipeline data and the significance of the Pfizer partnership valued at up to USD 10.5 billion in total deal value.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1140794164?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140794164","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Innovent Biologics Rises 3.01% in Regular Trading, IBI3003 Phase III First Patient Dosing Continues to Drive Sentiment","media":"Market Focus","content":"<p><p>On June 24, Innovent Biologics rose 3.01% in regular trading, trading at HKD 78.3/share, with turnover of HKD 64.46 million. The stock extended gains following the company's announcement that IBI3003, a GPRC5D/BCMA/CD3 trispecific antibody for the treatment of multiple myeloma, completed first patient dosing in its pivotal Phase III clinical trial.</p><p>This milestone marks a critical step toward clinical application for the innovative therapy. The catalyst has sustained market enthusiasm over consecutive sessions. Meanwhile, the broader biotechnology sector rallied in tandem, with BeiGene up 2.86% and Akeso up 1.4%, providing additional sector-level support. Separately, JPMorgan recently increased its position in the company by approximately 1.07 million shares at HKD 75.40 per share, while Xingye Securities maintained a Buy rating, citing strong pipeline data and the significance of the Pfizer partnership valued at up to USD 10.5 billion in total deal value.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Innovent Biologics Rises 3.01% in Regular Trading, IBI3003 Phase III First Patient Dosing Continues to Drive Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Innovent Biologics Rises 3.01% in Regular Trading, IBI3003 Phase III First Patient Dosing Continues to Drive Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-24 09:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 24, Innovent Biologics rose 3.01% in regular trading, trading at HKD 78.3/share, with turnover of HKD 64.46 million. The stock extended gains following the company's announcement that IBI3003, a GPRC5D/BCMA/CD3 trispecific antibody for the treatment of multiple myeloma, completed first patient dosing in its pivotal Phase III clinical trial.</p><p>This milestone marks a critical step toward clinical application for the innovative therapy. The catalyst has sustained market enthusiasm over consecutive sessions. Meanwhile, the broader biotechnology sector rallied in tandem, with BeiGene up 2.86% and Akeso up 1.4%, providing additional sector-level support. Separately, JPMorgan recently increased its position in the company by approximately 1.07 million shares at HKD 75.40 per share, while Xingye Securities maintained a Buy rating, citing strong pipeline data and the significance of the Pfizer partnership valued at up to USD 10.5 billion in total deal value.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1140794164","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140794164","pubTimestamp":1782264996,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 24, Innovent Biologics rose 3.01% in regular trading, trading at HKD 78.3/share, with turnover of HKD 64.46 million. The stock extended gains following the company's announcement that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"动静快讯|信达生物常规交易涨3.01%IBI3003三期首例患者给药持续带动情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On June 24, Innovent Biologics rose 3.01% in regular trading, trading at HKD 78.3/share, with turnover of HKD 64.46 million. The stock extended gains following the company's announcement that IBI3003, a GPRC5D/BCMA/CD3 trispecific antibody for the treatment of multiple myeloma, completed first patient dosing in its pivotal Phase III clinical trial.This milestone marks a critical step toward clinical application for the innovative therapy. The catalyst has sustained market enthusiasm over consecutive sessions. Meanwhile, the broader biotechnology sector rallied in tandem, with BeiGene up 2.86% and Akeso up 1.4%, providing additional sector-level support. Separately, JPMorgan recently increased its position in the company by approximately 1.07 million shares at HKD 75.40 per share, while Xingye Securities maintained a Buy rating, citing strong pipeline data and the significance of the Pfizer partnership valued at up to USD 10.5 billion in total deal value.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140794164","isCrawlerRequest":true}